Aberdeen Group plc decreased its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 89.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 95,470 shares of the company’s stock after selling 824,353 shares during the quarter. Aberdeen Group plc’s holdings in Zoetis were worth $6,667,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of ZTS. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Zoetis during the 2nd quarter valued at $25,000. Dunhill Financial LLC grew its holdings in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis in the 1st quarter worth $28,000. First Command Advisory Services Inc. grew its holdings in shares of Zoetis by 3,881.8% in the 3rd quarter. First Command Advisory Services Inc. now owns 438 shares of the company’s stock worth $31,000 after acquiring an additional 427 shares during the last quarter. Finally, Wellington Grp LLC raised its position in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the period. Institutional investors own 92.80% of the company’s stock.
More Zoetis News
Investors following ZTS have been watching these news items:
- Positive Sentiment: The USDA licensed Zoetis’s Poulvac Procerta HVT-ND-ILT vaccine for chickens, a three-disease product that adds to its poultry-health offerings and could create a new commercial opportunity. The articles do not specify expected sales or timing. Zoetis Receives USDA License for Poulvac Procerta HVT-ND-ILT Vaccine for Chickens
- Neutral Sentiment: Barclays remains at Hold, signaling a cautious view rather than a fresh upgrade or downgrade. Barclays Remains a Hold on Zoetis
- Negative Sentiment: Coverage flagged the prospect of weak veterinary visits, a potential headwind for demand for Zoetis’s animal-health products; the article says the company is relying on new products for growth. Zoetis Braces for Weak Vet Visits, Bets on New Products for Growth
Analysts Set New Price Targets
View Our Latest Research Report on ZTS
Zoetis Trading Down 5.5%
Shares of NYSE:ZTS opened at $80.85 on Friday. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. The stock’s 50-day moving average is $77.04 and its 200-day moving average is $90.76. The company has a market cap of $32.85 billion, a P/E ratio of 13.75, a P/E/G ratio of 1.24 and a beta of 0.67. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.24. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. Zoetis’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.70 earnings per share. Equities research analysts predict that Zoetis Inc. will post 6.29 earnings per share for the current year.
Zoetis Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Friday, October 30th. Zoetis’s payout ratio is 36.05%.
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
